Back to Search Start Over

Patterns of treatment and costs associated with transfusion burden in patients with myelodysplastic syndromes

Authors :
Amy E. DeZern
Steven R. Arikian
B. Douglas Smith
Jianyi Lee
Syed Rizvi
Andy Surinach
Frank A. Corvino
Gary Binder
Source :
Leukemia & Lymphoma. 58:2649-2656
Publication Year :
2017
Publisher :
Informa UK Limited, 2017.

Abstract

Transfusion dependence (TD) among myelodysplastic syndromes (MDS) patients negatively impacts survival and health-related quality of life. We evaluated cost patterns of MDS care during TD and transfusion independence (TI). MDS patients were identified from a US claims database (2008-2013). TD was defined as ≥2 consecutive 8-week periods with ≥1 claim during each, and no interim 56-day period without transfusion; TI as 8 subsequent transfusion-free weeks; and transfusion frequency as the mean interval between transfusions during the TD period. 13,741 patients were included; 19% were TD and 70% had a mean interval between transfusions of ≤28 days. During a 2-year period, TD patients incurred a mean total cost of $17,815/patient-month; 53% higher for those with ≤28 days ($19,498) vs. 28 days ($12,717) between transfusions. Among patients who achieved TI, mean total cost was $7874/patient-month. For TD-MDS patients, cost increases are proportional to transfusion frequency and achieving TI yields economic benefits.

Details

ISSN :
10292403 and 10428194
Volume :
58
Database :
OpenAIRE
Journal :
Leukemia & Lymphoma
Accession number :
edsair.doi.dedup.....8109b05901625bf9e84171c79b588ca4
Full Text :
https://doi.org/10.1080/10428194.2017.1312372